Index

• K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
• London doctors become first in the UK to ‘livestream’ surgery using robot
• Biotech raises funds to find cancer treatments using transgenic mice
• T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment
• Capital Rx and Vida Health Partner to Launch Rx Activate, a High-Touch Chronic Condition Management Program
• NFlection Therapeutics Announces Positive Results from Phase 2b Study of NFX‑179 Topical Gel in the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1
• Behavioral Health AI Leader Eleos Health Raises $40M Series B Round to Expand CareOps Automation Footprint
• AppliedVR is betting a new study could strengthen the case for insurance coverage of its VR chronic pain treatment
• OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
• AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
• Prime Medicine showcases its first in vivo editing data in monkeys and mice
• ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
• FDA lifts clinical hold on LDL-lowering drug from Verve Therapeutics
• Warmly pivots from Zoom tool to directing warm leads to sales
• NodThera announces first patients dosed in a Phase Ib/IIa cardiovascular risk trial of NLRP3 inflammasome inhibitor NT-0796
• AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
• Rippl and McLean Hospital collaborate to build ‘first of its kind’ dementia training program
• Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
• Kyowa Kirin to Acquire Orchard Therapeutics
• Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19
• Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
• Doceree raises $35 million in Series B funding, led by Creaegis with participation from Eight Roads Ventures and F-Prime Capital
• Avalyn raises $175M to test inhaler versions of IPF medicines in PhII trials
• Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
• Labcorp backs Adela’s $48M Series A1 to advance methylation-based head and neck cancer test
• Peptone: finding opportunity in disorder
• All Pregnant Women Should Be Screened for Blood-Pressure Disorders, U.S. Advisers Say
• Equip nabs additional investment to expand virtual eating disorder treatment services to adult patients
• Neumora Therapeutics Announces Pricing of Initial Public Offering
• Owkin and Tribun Health Launch Strategic Partnership to Accelerate Access to AI Solutions for Diagnosis and Pharma Research
• Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
• Eleos Health and KCare Join Forces to Improve Clinician Support with CareOps Automation
• Substance-use treatment startup Better Life Partners completes $26.5M Series B fundraise
• Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023
• Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia
• Firefly grows in wake of healthcare disruptions in southeastern Mass.
• Madaket Health Releases Provider Data Exchange to Help Payers Remain Compliant with the No Surprises Act
• TraceLink Collaborates with GS1 US to Author GS1 US Addendum Guidance and XML Examples for GS1 US DSCSA Implementation Guideline R1.3 to Support EPCIS Data Exchange
• Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
• Radiopharmaceuticals for cancer: Making radiation precise
• Health Plan Alliance Selects 1upHealth as Preferred Health Data Interoperability Partner
• Memorial Hermann Health System Makes a Strategic Investment in Capital Rx Customer Solutions Platform
• SoftBank-backed Proximie launches virtual robotic-assisted surgery training course
• Talkiatry and NOCD Team up to Strengthen OCD Care Journeys
• Simon Data Raises Series D Funding Round to Further Develop World’s First Fully-Connected CDP
• Better Life Partners Lands $26.5M for Virtual SUD, Mental Health Platform
• Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
• Talkiatry, NOCD Strike Partnership To Support Patients With OCD
• Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D
• With ISO certification, Owkin demonstrates commitment to utmost quality with its AI solutions for digital pathology
• Sironax Announces Closing of $200 Million Series B Financing
• Member Spotlight: F-Prime Capital
• Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
• Patina teams with Humana to expand reach of convenient, relationship-centered primary care for people with Medicare
• Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect
• VR helps brain tumor patients overcome “scanxiety” before brain scans, study finds
• Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
• ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO’s AlphaDirect™ Technology
• AppliedVR and National Cancer Institute Collaborate on Research Evaluating Virtual Reality for Reducing Anxiety in Primary Brain Tumor Patients During Imaging Services
• Centivo Launches Partnership with SSM Health
• Tenpoint Therapeutics launches with $70M to restore vision with stem cell therapies and ‘reprogramming’ medicines
• NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
• Zus Health Joins Civitas Networks for Health
• Patina brings innovative primary care for people 65+ to Charlotte region; designed to help individuals thrive & remain independent
• Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
• Centivo Launches Partnership with SSM Health in the Fond du Lac Market to Offer Wisconsin Businesses and Employees More Affordable, High-Quality Healthcare
• China NMPA approves RareStone’s pitolisant (Wakix) for the treatment of narcolepsy
• Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
• Innovent and IASO Bio Announce the NMPA Approval of FUCASO®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
• F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn
• K36 Therapeutics raises $70M in Series B to fund multiple myeloma research
• K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
• Menopause care is still a largely untapped market. Here’s why investors and startups should dive in
• First AI-generated drug enters human clinical trials, targeting chronic lung disease patients
• Biotech begins human trials of drug designed by artificial intelligence
• First Drug Discovered and Designed with Generative AI Enters Phase II Trials, with First Patients Dosed
• Harvard Medical School, RareCyte developing multiplex imaging for clinical pathology
• Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors
• Castor Appoints New CFO to Drive Transformative Growth
• Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
• TIME100 Most Influential Companies 2023: Equip
• Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
• ARTBIO: manufacturing strategy to lead on lead-212 radiotherapies
• Ultragenyx opens new gene therapy manufacturing site in Massachusetts
• ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential
• ARTBIO emerges with $23M to make radioligand therapies for prostate cancer, with field still in ‘early days’
• WelbeHealth’s Michael Le On The Future Of Innovative At-Home Care Models
• Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and Services
• India’s Enzene Biosciences unveils $50M New Jersey plant project, plans to hire 300
• Equip Names Nikia Bergan as the Company’s First President